[Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias].
The effect of Misclerone (clofibrate) was studied in 127 patients with different types of hyperlipoproteinemia treated with the drug for 1 month and longer. On the basis of the obtained data it was concluded that Misclerone is effective both in patients with isolated disorders in cholesterol metabolism (Type II), and in those with cholesterol and triglycerides metabolism disorders (Types IIb and III), and in those with prevailing triglycerides metabolism disorders (Type IV). The efficacy of the drug in Type II hyperlipoproteinemia is determined by the degree and nature of metabolic disorders of low density lipoproteins.
D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D002914:Chylomicrons; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
Primenenie kisklerona u bol'nykh ishemicheskoĭ bolezn'iu serdtsa s raznymy tipami giperlipoproteidemiĭ